Pemetrexed Viatris 25 mg/ml

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

IFCT-2101 MASTERPROTOCOL ALK A phase II randomized, open-labelled, multicenter study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non-small cell lung cancer